Recombinant production of hormonally active human insulin from pre-proinsulin by Tetrahymena thermophila.


Journal

Enzyme and microbial technology
ISSN: 1879-0909
Titre abrégé: Enzyme Microb Technol
Pays: United States
ID NLM: 8003761

Informations de publication

Date de publication:
Oct 2023
Historique:
received: 23 03 2023
revised: 03 08 2023
accepted: 04 08 2023
medline: 4 9 2023
pubmed: 11 8 2023
entrez: 10 8 2023
Statut: ppublish

Résumé

Alternative cell factories, such as the unicellular ciliate eukaryotic Tetrahymena thermophila, may be required for the production of protein therapeutics that are challenging to produce in conventional expression systems. T. thermophila (Tt) can secrete proteins with the post-translational modifications necessary for their function in humans. In this study, we tested if T. thermophila could process the human pre-proinsulin to produce hormonally active human insulin (hINS) with correct modifications. Flask and bioreactor culture of T. thermophila were used to produce the recombinant Tt-hINS either with or without an affinity tag from a codon-adapted pre-proinsulin sequence. Our results indicate that T. thermophila can produce a 6 kDa Tt-hINS monomer with the appropriate disulfide bonds after removal of the human insulin signal sequence or endogenous phospholipase A signal sequence, and the C-peptide of the human insulin. Additionally, Tt-hINS can form 12 kDa dimeric, 24 kDa tetrameric, and 36 kDa hexameric complexes. Tt-hINS-sfGFP fusion protein was localized to the vesicles within the cytoplasm and was secreted extracellularly. Assessing the affinity-purified Tt-hINS activity using the in vivo T. thermophila extracellular glucose drop assay, we observed that Tt-hINS induced a significant reduction (approximately 21 %) in extracellular glucose levels, indicative of its functional insulin activity. Our results demonstrate that T. thermophila is a promising candidate for the pharmaceutical and biotechnology industries as a host organism for the production of human protein drugs.

Identifiants

pubmed: 37562115
pii: S0141-0229(23)00111-4
doi: 10.1016/j.enzmictec.2023.110303
pii:
doi:

Substances chimiques

Proinsulin 9035-68-1
Recombinant Proteins 0
Protein Sorting Signals 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110303

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no competing interests.

Auteurs

Ayça Fulya Üstüntanır Dede (AF)

Department of Biology, Institute of Graduate Programs, Eskisehir Technical University, Yunus Emre Campus, Eskisehir 26470, Turkey,. Electronic address: aycafulya@gmail.com.

Muhittin Arslanyolu (M)

Department of Biology, Faculty of Sciences, Eskisehir Technical University, Yunus Emre Campus, Eskisehir 26470, Turkey. Electronic address: marslanyolu@eskisehir.edu.tr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH